123 related articles for article (PubMed ID: 2279544)
1. Interferon alpha-2a in cutaneous T-cell lymphoma.
Vegna ML; Papa G; Defazio D; Pisani F; Coppola G; De Pità O; Puddu P; Ferranti G; Simoni R; Mandelli F
Eur J Haematol Suppl; 1990; 52():32-5. PubMed ID: 2279544
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up in 51 patients with mycosis fungoides and Sézary syndrome treated by interferon-alfa.
Jumbou O; N'Guyen JM; Tessier MH; Legoux B; Dréno B
Br J Dermatol; 1999 Mar; 140(3):427-31. PubMed ID: 10233261
[TBL] [Abstract][Full Text] [Related]
3. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?
Papa G; Tura S; Mandelli F; Vegna ML; Defazio D; Mazza P; Zinzani PL; Simoni R; DePita O; Ferranti G
Br J Haematol; 1991 Oct; 79 Suppl 1():48-51. PubMed ID: 1931709
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome.
Kohn EC; Steis RG; Sausville EA; Veach SR; Stocker JL; Phelps R; Franco S; Longo DL; Bunn PA; Ihde DC
J Clin Oncol; 1990 Jan; 8(1):155-60. PubMed ID: 2295906
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Linnoila IR; Fischmann AB; Schechter GP; Cotelingam JD; Steinberg SM; Ghosh BC; Stocker JL; Bastian A
J Clin Oncol; 1994 Oct; 12(10):2051-9. PubMed ID: 7931473
[TBL] [Abstract][Full Text] [Related]
6. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
7. Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides.
Simoni R; Cavalieri R; Coppola G; Ricciotti L; De Pità O; Criscuolo D; Covelli A; Papa G; Mandelli F
J Biol Regul Homeost Agents; 1987; 1(2):93-9. PubMed ID: 3504088
[TBL] [Abstract][Full Text] [Related]
8. The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate.
Dréno B; Claudy A; Meynadier J; Verret JL; Souteyrand P; Ortonne JP; Kalis B; Godefroy WY; Beerblock K; Thill L
Br J Dermatol; 1991 Nov; 125(5):456-9. PubMed ID: 1751352
[TBL] [Abstract][Full Text] [Related]
9. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy.
Stadler R; Otte HG
Recent Results Cancer Res; 1995; 139():391-401. PubMed ID: 7597306
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome.
Foss FM; Ihde DC; Breneman DL; Phelps RM; Fischmann AB; Schechter GP; Linnoila I; Breneman JC; Cotelingam JD; Ghosh BC
J Clin Oncol; 1992 Dec; 10(12):1907-13. PubMed ID: 1453206
[TBL] [Abstract][Full Text] [Related]
12. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
13. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma.
Zachariae H; Thestrup-Pedersen K
J Invest Dermatol; 1990 Dec; 95(6 Suppl):206S-208S. PubMed ID: 2258637
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi E; Redelotti R; Peserico A; Monfardini S; Salvagno L
Cancer; 2002 Aug; 95(3):569-75. PubMed ID: 12209749
[TBL] [Abstract][Full Text] [Related]
15. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome.
Avilés A; Nambo MJ; Neri N; Castañeda C; Cleto S; Gonzalez M; Huerta-Guzmán J
Cancer Biother Radiopharm; 2007 Dec; 22(6):836-40. PubMed ID: 18158775
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.
Schiller M; Tsianakas A; Sterry W; Dummer R; Hinke A; Nashan D; Stadler R
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1841-1847. PubMed ID: 28557110
[TBL] [Abstract][Full Text] [Related]
17. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of interferon α-2a combined with phototherapy for patients with early-stage mycosis fungoides - a single-arm prospective study in 13 patients.
Song H; Hu Z; Zhang S; Yang L; Feng J; Lu L; Liu Y; Wang T
J Dermatolog Treat; 2024 Dec; 35(1):2350231. PubMed ID: 38754985
[No Abstract] [Full Text] [Related]
19. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center.
Querfeld C; Mehta N; Rosen ST; Guitart J; Rademaker A; Gerami P; Kuzel TM
Leuk Lymphoma; 2009 Dec; 50(12):1969-76. PubMed ID: 19860617
[TBL] [Abstract][Full Text] [Related]
20. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group.
Rupoli S; Barulli S; Guiducci B; Offidani M; Mozzicafreddo G; Simonacci M; Filosa G; Giacchetti A; Ricotti G; Brandozzi G; Cataldi I; Serresi S; Ceschini R; Bugatti L; Offidani A; Giangiacomi M; Brancorsini D; Leoni P
Haematologica; 1999 Sep; 84(9):809-13. PubMed ID: 10477454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
